Alkermes (ALKS) Cash & Current Investments (2010 - 2026)
Alkermes (ALKS) posted quarterly Cash & Current Investments of $656.6 million for Q2 2026, down 35.36% year-over-year from $1.0 billion in Q2 2025, and up 28.27% quarter-over-quarter from $511.9 million in Q1 2026.
Alkermes (ALKS) Cash & Current Investments (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Cash & Current Investments for 17 consecutive years, with $656.6 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash & Current Investments fell 35.36% year-over-year to $656.6 million; the TTM figure through Jun 2026 stood at $656.6 million (down 35.36% YoY), while the FY2025 annual figure was $1.1 billion, up 48.97% from the prior year.
- Cash & Current Investments advanced to $656.6 million in Q2 2026 per ALKS's latest filing, from $511.9 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $1.1 billion in Q4 2025 and bottomed at $511.9 million in Q1 2026.
- Historically, Cash & Current Investments has averaged $776.2 million across 5 years, with a median of $762.6 million in 2023.
- Annual changes were most pronounced in 2023 — Cash & Current Investments soared 53.25% — and 2026, when it tumbled 42.1%.
- Alkermes' Cash & Current Investments stood at $608.5 million in 2022, then advanced by 27.12% to $773.5 million in 2023, then slipped by 2.82% to $751.7 million in 2024, then surged by 48.97% to $1.1 billion in 2025, then sank by 41.37% to $656.6 million in 2026.
- Business Quant data shows ALKS's Cash & Current Investments at $656.6 million in Q2 2026, $511.9 million in Q1 2026, and $1.1 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - | 963.33 Mn |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 1.68 Bn |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn | 5.80 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 2.66 Bn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 389.80 Mn |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - | 164.00 Mn |
| 10 | Alkermes | 8.17 Bn | 7.51 Bn | 397.90 Mn | 656.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 656.58 Mn |
| Mar 31, 2026 | 511.86 Mn |
| Dec 31, 2025 | 1.12 Bn |
| Sep 30, 2025 | 1.11 Bn |
| Jun 30, 2025 | 1.02 Bn |
| Mar 31, 2025 | 884.02 Mn |
| Dec 31, 2024 | 751.67 Mn |
| Sep 30, 2024 | 908.86 Mn |
| Jun 30, 2024 | 876.12 Mn |
| Mar 31, 2024 | 745.05 Mn |
| Dec 31, 2023 | 773.49 Mn |
| Sep 30, 2023 | 889.15 Mn |
| Jun 30, 2023 | 829.05 Mn |
| Mar 31, 2023 | 600.46 Mn |
| Dec 31, 2022 | 608.47 Mn |
| Sep 30, 2022 | 580.18 Mn |
| Jun 30, 2022 | 580.97 Mn |
| Mar 31, 2022 | 528.87 Mn |
| Dec 31, 2021 | 536.31 Mn |
| Sep 30, 2021 | 560.30 Mn |